Chunzhang Yang

Cystic fibrosis transmembrane conductance regulator expression in human spinal and sympathetic ganglia.

Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl.

Carbon dioxide influence on nitric oxide production in endothelial cells and astrocytes: cellular mechanisms.

Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.

Proteomic identification of glutamine synthetase as a differential marker for oligodendrogliomas and astrocytomas.

Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease.

β-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas.

Neuronatin in a subset of glioblastoma multiforme tumor progenitor cells is associated with increased cell proliferation and shorter patient survival.

An innovative approach to the treatment of Gaucher disease and possibly other metabolic disorders of the brain.

Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function.

Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia.

CNTF receptor subunit α as a marker for glioma tumor-initiating cells and tumor grade: laboratory investigation.

A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma.

Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones.

Proteostasis modulators prolong missense VHL protein activity and halt tumor progression.

Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas.

Regulation and dysregulation of astrocyte activation and implications in tumor formation.

New syndrome of paraganglioma and somatostatinoma associated with polycythemia.

Novel homozygous VHL mutation in exon 2 is associated with congenital polycythemia but not with cancer.

First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome.

Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms.

Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury.

Novel compound VHL heterozygosity (VHL T124A/L188V) associated with congenital polycythaemia.

Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction.

Overexpression of arginine transporter CAT-1 is associated with accumulation of L-arginine and cell growth in human colorectal cancer tissue.

Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones.

Tumor derived vasculogenesis in von Hippel-Lindau disease-associated tumors.

De novo VHL germline mutation detected in a patient with mild clinical phenotype of von Hippel-Lindau disease.

Maotai ameliorates diethylnitrosamine-initiated hepatocellular carcinoma formation in mice.

Von hippel-lindau disease associated pulmonary carcinoid with cranial metastasis.

Ocular Manifestations of Hypoxia-Inducible Factor-2α Paraganglioma-Somatostatinoma-Polycythemia Syndrome.

Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia.

A morphologic and semi-quantitative technique to analyze synthesis and release of specific proteins in cells.

Fab fragment glycosylated IgG may play a central role in placental immune evasion.

Cell transcriptional state alters genomic patterns of DNA double-strand break repair in human astrocytes.

Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation.

New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.

LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential.

Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma.

Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment.

Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy.

Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells.

Hypoxia and glioblastoma therapy.

Somatic IDH1 mutation in a pituitary adenoma of a patient with Maffucci syndrome.

Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas.

Hypotaurine evokes a malignant phenotype in glioma through aberrant hypoxic signaling.

Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia.

Application of Peptide Nucleic Acid-based Assays Toward Detection of Somatic Mosaicism.

HIF2A gain-of-function mutations detected in duodenal gangliocytic paraganglioma.

ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.

Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome.

Chemosensitivity of IDH1 mutant gliomas due to an impairment in PARP1-mediated DNA repair.

The p38 signaling pathway mediates quiescence of glioma stem cells by regulating epidermal growth factor receptor trafficking.

Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway.

Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha.